<DOC>
	<DOC>NCT02945215</DOC>
	<brief_summary>Randomised, double-blind, parallel group study to compare PK and PD profiles between IBI301 and rituximab in patients with CD20+ B-cell Lymphoma</brief_summary>
	<brief_title>A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>1. CD20positive Bcell lymphoma. 2. 18 years to 65 years. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. 4. Signed an informed consent. 5. Obtained CR (complete remission) or CRu (uncertain complete remission) after the prior therapy. 1. Participation in another interventional clinical trial in the past 28 days. 2. Known allergic reactions against monoclonal antibody or rituximab. 3. Rituximab and other antiCD20 monoclonal antibody used in the past 4 months. 4. Blood concentration of Rituximab&gt;24ug/ml. 5. HIV positive patients. 6. HCV antigen and antibody positive. 7. Acute and chronic hepatitis B virus infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>